TenX Keane Acquisition
Why Robinhood?
You can watch TENK and buy or sell other stocks, ETFs, and their options commission-free!About TENK
Citius Oncology, Inc. is a biopharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.
TENK Key Statistics
Stock Snapshot
TenX Keane Acquisition(TENK) stock is priced at $0.93, giving the company a market capitalization of 98.26M. It carries a P/E multiple of -1.82.
During the trading day, TenX Keane Acquisition(TENK) stock saw an opening price of —, a peak of —, and a bottom of —.
Trading activity shows a volume of 0, compared to an average daily volume of 33.43K.
The stock's 52-week range extends from a low of $0.49 to a high of $2.25.
The stock's 52-week range extends from a low of $0.49 to a high of $2.25.
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.